



CASE ON/4-32557A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1624

BREITENSTEIN ET AL.

APPLICATION NO: 10/520,359

FILED: SEPTEMBER 12, 2005

FOR: INHIBITORS OF TYROSINE KINASES

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7898

Date:

Aug 25, 2006

Lydia T. McNally
Attorney for Applicants
Reg. No. 36,214



CASE ON/4-32557A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV8233636234S
Express Mail Label Number

August 25, 2006
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
BREITENSTEIN ET AL.

Art Unit: 1624

INTERNATIONAL APPLICATION NO: PCT/EP03/07198

FILED: 4 JULY 2003

U.S. APPLICATION NO: 10/520,359

35 USC §371 DATE: 12 SEPTEMBER 2005

FOR: INHIBITORS OF TYROSINE KINASES

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c). A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Copies of these references are enclosed herewith.


08/30/2006 EFLORES 00000055 190134 10520359

01 FC:1806 180.00 DA

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7898



Lydia T. McNally
Attorney for Applicants
Reg. No. 36,214

Date: *Aug 25, 2006*

ATTY. DOCKET NO.

ON/4-32557A

APPLICATION NO.

10/520,359

APPLICANT

BREITENSTEIN ET AL.

FILING DATE

SEPTEMBER 12, 2005

Group
1614

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,516,775	5/14/96	Zimmermann et al.			
	AB	2006/0014742	1/19/06	Asaki et al.			
	AC	5,521,184	5/28/96	Zimmermann			
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	02/46170	6/13/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	02/46171	6/13/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AO	0 588 762	3/23/94	EP (English equivalent is US 5,516,775)			<input type="checkbox"/>	<input type="checkbox"/>
	AP	95/09853	4/13/95	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	2004/002963	1/8/04	WO (English equivalent is US 2006/0014742)			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Zimmermann et al., "Potent and Selective Inhibitors of the ABL-Kinase: Phenylamino-Pyrimidine (PAP) Derivatives," Bioorganic & Medical Chemistry Letters, Vol. 7, No. 2, pp. 187-192 (1997)
	AS	Zimmermann et al., "Phenylamino-Pyrimidine (PAP) - Derivatives: A New Class of Potent and Highly Selective PDGF-Receptor Autophosphorylation Inhibitors," Bioorganic & Medicinal Chemistry Letters, Vol. 6, No. 11, pp. 1221-1226 (1996)
	AT	Paul et al., "Preparation of Substituted N-Phenyl-4-aryl-2-pyrimidinamines as Mediator Release Inhibitors," J. Med. Chem., Vol. 36, pp. 2716-2725 (1993)


EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
ON/4-32557A
APPLICATION NO.
10/520,359
APPLICANT
BREITENSTEIN ET AL.
FILING DATE
SEPTEMBER 12, 2005Group
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BM	JP 6-184116	7/5/94	JP (English equivalent is US 5,516,775)			<input type="checkbox"/>	<input type="checkbox"/>
	BN						<input type="checkbox"/>	<input type="checkbox"/>
	BO						<input type="checkbox"/>	<input type="checkbox"/>
	BP						<input type="checkbox"/>	<input type="checkbox"/>
	BQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BR	Bhat et al., "Interactions of CBL with BCR-ABL and CRKL in BCR-ABL transformed Myeloid Cells," The Journal of Biological Chemistry, Vol. 272, No. 26, Issue of June 27, pp. 16170-16175 (1997)
	BS	Shibuya et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (<i>flt</i>) closely related to the <i>fms</i> family," Oncogene, Vol. 5, pp. 519-524 (1990)
	BT	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.